AI to Prioritise 16 Cancer Drug Candidates Targeting Bacterial DnaK
Artificial intelligence is being deployed to evaluate 16 potential cancer drug candidates targeting bacterial DnaK, aiming to select compounds for experimental testing.
-
Key Clinical Takeaways:
- DnaK Therapeutics partnered with GATC Health in September 2026 to assess 16 potential cancer drug candidates using predictive artificial intelligence.
- The programme focuses on bacterial DnaK, a molecular chaperone protein implicated in chemotherapy resistance by impairing human anti-cancer drugs like cisplatin and 5-fluorouracil.
- GATC Health reported that its Operon AI platform achieved 91 percent specificity for negative target activation and 86 percent sensitivity for positive target activation during blind validations.
Selecting Drug Candidates
Selecting which drug candidates to advance remains a major challenge in early-stage discovery. Promising activity against a target does not always justify further development when safety, selectivity, and therapeutic effects remain uncertain. DnaK Therapeutics partnered with GATC Health in September 2026 to evaluate 16 potential cancer drug candidates using predictive artificial intelligence, Drug Target Review reported.
The collaboration aims to identify a smaller group of compounds for experimental testing as DnaK Therapeutics works towards selecting a lead development candidate. Speaking to Drug Target Review, Dr Rahul Gupta, President of GATC Health, explained why candidate selection requires more than identifying the compound with the strongest target activity.
“At this stage, the question is not simply which compound looks most active against the target. We want to understand which candidates have the strongest overall development profile,” Gupta told Drug Target Review.
Bacterial DnaK Mechanisms
DnaK is a bacterial heat shock protein belonging to the Hsp70 family of molecular chaperones. The protein facilitates correct protein folding, prevents protein aggregation, and helps bacteria survive under stressful conditions. Research suggests that bacterial DnaK can also interfere with biological processes in human cells, including pathways involved in DNA repair and tumour suppression.
In a study published in the Journal of Translational Medicine on March 12, 2024, researchers investigated how DnaK proteins from Mycoplasma fermentans and Fusobacterium nucleatum affected responses to chemotherapy drugs. The authors, including DnaK Therapeutics scientific founders Dr Francesca Benedetti, Dr Robert Gallo, and Dr Davide Zella, found that the proteins reduced the anticancer activity of cisplatin and 5-fluorouracil in human colorectal and gastric cancer cell lines.
Evaluating Operon AI Predictions
GATC Health uses its Operon AI platform to assess compounds and generate Derisq reports examining predicted efficacy, safety, and potential off-target effects. According to Gupta, the platform integrates multiomic datasets, preclinical evidence, disease biology, patient pathology, and drug-interaction data to model interactions between candidates and human biological systems.
To evaluate reliability, GATC Health benchmarked its technology through a blind validation with the University of California, Irvine. According to Gupta, the platform achieved 91 percent specificity for negative target activation and 86 percent sensitivity for positive target activation when predicting molecule-target activity from previously unseen chemical structures.
Gupta stressed that platform performance should not be treated as proof that individual predictions are correct.
“For a programme like DnaK’s, the prediction is best viewed as decision support. We look for consistency across different dimensions of the analysis, such as efficacy, safety, mechanism and off-target risk, and then use the subsequent experimental work as the critical test of whether those predictions hold up in the laboratory,” Gupta told Drug Target Review.
Predictive AI Guides Biotech Resource Allocation
For smaller biotechnology companies, advancing multiple compounds through preclinical testing requires substantial investment. Gupta said that predictive AI helps researchers decide where to concentrate scarce time and capital when multiple compounds look promising based on conventional measures.
Dr Robert Gallo, co-founder of DnaK Therapeutics, expressed a similar concern in the companies’ September announcement, stating, “We have a number of potentially viable drug candidates, but we need to determine which are the most beneficial, effective, and safest before we invest substantial resources.” The computational analysis aims to guide DnaK Therapeutics’ experimental testing as the company works towards selecting a lead development candidate.
GATC Health utilizes its proprietary Operon platform to simulate the full complexity of human biology before clinical testing begins. The discovery engine integrates multiomic data to forecast therapeutic potential, identify risk factors, and simulate trial outcomes, aiming to reduce preclinical costs significantly while accelerating the development timeline.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.